ArticleBMC cancer2025

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial.

Vincenzo Nasca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.